Arkolith/Insider Trading/AMLX/Form 4

Klee Justin B.

Co-Chief Executive Officer, DirectorAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Oct 2, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$431K
Net Open-Market Flow
-$431K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 30, 2025Sell(S)30K$14.37$428K3.3M
Sep 30, 2025Sell(S)200$15.01$3K3.3M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-228343) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML